Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single-dose, Dose-escalation Phase I/II Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GC310 Adeno-associated Virus Injection in the Treatment of Patients With Wilson's Disease (WD)

NCT07173933 is registered in ClinicalTrials.gov with GeneCradle Inc as lead sponsor.

NCT NCT07173933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07173933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single-dose, Dose-escalation Phase I/II Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GC310 Adeno-associated Virus Injection in the Treatment of Patients With Wilson's Disease (WD)
Lead sponsor
GeneCradle Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
October 31, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wilson disease